Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: A pharmacokinetics/pharmacodynamics-based approach

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6343-6348

  Pea, Federico ^a   Viale, Pierluigi ^b   Cojutti, Piergiorgio ^a   Furlanut, Mario ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DOSE CALCULATION; FEMALE; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; CREATININE; CRITICAL ILLNESS; ENTEROBACTERIACEAE; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NOMOGRAMS; SPECTROPHOTOMETRY, ULTRAVIOLET; THIENAMYCINS;

EID: 84869205436     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01291-12     Document Type: Article

References (48)

1. Ariano RE, et al. 2005. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann. Pharmacother. 39:32-38.
2. Baptista JP, et al. 2011. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit. Care 15:R139.
3. Baughman RP. 2009. The use of carbapenems in the treatment of serious infections. J. Intensive Care Med. 24:230-241.
4. Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM. 2010. Stability of meropenem and doripenem solutions for administration by continuous infusion. J. Antimicrob. Chemother. 65:1073-1075.
5. Boucher HW, et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
6. Bulik CC, et al. 2010. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 54:804-810.
7. Bulik CC, Nicolau DP. 2010. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 54:4112-4115.
8. Canton R, et al. 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18:413-431.
9. Chytra I, et al. 2012. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit. Care 16:R113.
10. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
11. Coque TM, Baquero F, Canton R. 2008. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 13(48):pii=19044. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19044.
12. Daikos GL, Markogiannakis A. 2011. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin. Microbiol. Infect. 17:1135-1141.
13. Daikos GL, et al. 2007. Activity of imipenem against VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model. Clin. Microbiol. Infect. 13:202-205.
14. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. 2006. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 66:1-14.
15. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300.
16. EUCAST. 2011. Clinical breakpoints. European Committee on Antimicrobial Susceptibility, Vaxjo, Sweden. http://www.eucast.org/clinical-breakpoints/.
17. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, Lizan-Garcia M. 2008. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth. Intensive Care 36:674-680.
18. Goncalves-Pereira J, Povoa P. 2011. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit. Care 15:R206.
19. Hawkey PM, Livermore DM. 2012. Carbapenem antibiotics for serious infections. BMJ 344:e3236. doi:10.1136/bmj.e3236.
20. Ho VP, et al. 2011. Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection. Surg. Infect. (Larchmt.) 12:325-327.
21. Keel RA, Sutherland CA, Crandon JL, Nicolau DP. 2011. Stability of doripenem, imipenem and meropenem at elevated room temperatures. Int. J. Antimicrob. Agents 37:184-185.
22. Langgartner J, Vasold A, Gluck T, Reng M, Kees F. 2008. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med. 34:1091-1096.
23. Li C, Du X, Kuti JL, Nicolau DP. 2007. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob. Agents Chemother. 51:1725-1730.
24. Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases Pharmacists. 2006. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 26:1320-1332.
25. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. 2006. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to Gram-negative bacilli. Ann. Pharmacother. 40:219-223.
26. Mendez AS, Steppe M, Schapoval EE. 2003. Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J. Pharm. Biomed. Anal. 33:947-954.
27. Mouton JW, et al. 2011. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin. Microbiol. Infect. 18:E37-E45.
28. Nicolau DP. 2008. Carbapenems: a potent class of antibiotics. Expert Opin. Pharmacother. 9:23-37.
29. Nicolau DP. 2008. Pharmacokinetic and pharmacodynamic properties of meropenem. Clin. Infect. Dis. 47(Suppl 1):S32-S40.
30. Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP. 2007. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn. Microbiol. Infect. Dis. 57:153-161.
31. Park EJ, et al. 2012. A systematic comparison of Cockcroft-Gault and modification of diet in renal disease equations for classification of kidney dysfunction and dosage adjustment. Ann. Pharmacother. 46:1174-1187.
32. Pea F, et al. 2011. TDM-guided therapy with daptomycin and meropenem in a morbidly obese, critically ill patient. Ann. Pharmacother. 45:e37.
33. Pea F, Viale P. 2009. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock - does the dose matter? Crit. Care 13:214.
34. Pea F, Viale P, Furlanut M. 2005. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin. Pharmacokinet. 44:1009-1034.
35. Perrott J, Mabasa VH, Ensom MH. 2010. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann. Pharmacother. 44:557-564.
36. Pitout JD. 2010. Infections with extended-spectrum beta-lactamase- producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 70:313-333.
37. Polsfuss S, Bloemberg GV, Giger J, Meyer V, Hombach M. 2012. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum beta-lactamase production in clinical Enterobacteriaceae isolates. J. Antimicrob. Chemother. 67:159-166.
38. Pournaras S, et al. 2011. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int. J. Antimicrob. Agents 37:244-247.
39. Rahal JJ. 2009. Antimicrobial resistance among and therapeutic options against Gram-negative pathogens. Clin. Infect. Dis. 49(Suppl 1):S4-S10.
40. Roberts JA, et al. 2009. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J. Antimicrob. Chemother. 64:142-150.
41. Roberts JA, Norris R, Paterson DL, Martin JH. 2012. Therapeutic drug monitoring of antimicrobials. Br. J. Clin. Pharmacol. 73:27-36.
42. Schuck EL, Derendorf H. 2005. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev. Anti Infect. Ther. 3:361-373.
43. Souli M, et al. 2011. Efficacy of carbapenems against a metallo-beta-lactamase-producing Escherichia coli clinical isolate in a rabbit intraabdominal abscess model. J. Antimicrob. Chemother. 66:611-617.
44. Tam VH, Nikolaou M. 2011. A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design. PLoS Comput. Biol. 7:e1001043. doi:10.1371/journal.pcbi.1001043.
45. Tam VH, et al. 2005. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 49:4920-4927.
46. Udy AA, Roberts JA, Lipman J. 2011. Implications of augmented renal clearance in critically ill patients. Nat. Rev. Nephrol. 7:539-543.
47. Wang D. 2009. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrugresistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 33:290-291.
48. Zhanel GG, et al. 2007. Comparative review of the carbapenems. Drugs 67:1027-1052.